Trial Profile

A Phase 1, first in human trial assessing PLN-1474 for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PLN 1474 (Primary)
Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Pliant Therapeutics

Most Recent Events

16 Mar 2021 According to a Pliant Therapeutics media release, PLN-1474 Investigational New Drug (IND) Application has been transferred to Novartis who will be responsible for all future development, manufacturing, and commercialization activities.
16 Mar 2021 Results presented in a Pliant Therapeutics media release.
16 Mar 2021 Status changed from recruiting to completed according to an Pliant Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com